Results 121 to 130 of about 64,314 (239)

Unexpected multiple sclerosis‐like symptoms in a rheumatoid arthritis patient treated with Etanercept: A case report

open access: yesClinical Case Reports
Key Clinical Massage Although tumor necrosis factor (TNF) inhibitors are used to prevent autoimmune disease, but they can cause adverse effects. Multiple sclerosis syndrome is one of the rare complications following treatment with TNF inhibitor.
Ali Hosseinpour   +4 more
doaj   +1 more source

Etanercept suppresses TNF-α elevation following IOP elevation.

open access: yes, 2012
A, ELISA for TNF-α protein in the retina.
Sung Chul Lee (153672)   +7 more
core   +1 more source

Role of RIPK1/RIPK3/MLKL signalling pathway in sepsis‐associated acute kidney injury

open access: yesExperimental Physiology, EarlyView.
Abstract Sepsis‐associated acute kidney injury (SA‐AKI) is a common clinical syndrome in critically ill patients, and its high mortality rate is closely related to complex pathological mechanisms. Existing studies have shown that the pathophysiological process of SA‐AKI involves complex multi‐mechanism interactions, including an uncontrolled systemic ...
Huijun Yin, Jingyi Wang, Huirong Han
wiley   +1 more source

Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis

open access: yes, 2004
Etanercept (Enbrel) induces a rapid and sustained decline in disease activity in the majority of patients with refractory rheumatoid arthritis (RA). In these patients neutralization of TNFalpha and lymphotoxin (LT), previously termed TNFbeta is mediated ...
Terslev, L   +8 more
core   +1 more source

Safety of etanercept in elderly subjects with rheumatoid arthritis

open access: yes, 2009
Alfredomaria Lurati, Mariagrazia Marrazza, Katia Angela, Magda ScarpelliniFornaroli Hospital, Rheumatology Unit, Magenta, ItalyObjective: To report side effects seen in a clinical cohort of patients aged >65 years with rheumatoid arthritis (RA ...
Mariagrazia Marrazza   +3 more
core  

Exploring market dynamics of biological including biosimilar treatments for retinal diseases in Europe: An interrupted time‐series analysis

open access: yesActa Ophthalmologica, Volume 104, Issue 8, Page 926-939, December 2026.
Abstract Purpose To assess the impact of biosimilar ranibizumab and on‐patent faricimab market entry on pricing and utilization trends and describe national variation in off‐label bevacizumab use in Europe. Methods Interrupted time series analysis of quarterly sales data (Q1 2018–Q2 2024) in 11 European countries evaluated ranibizumab utilization and ...
Elif Car   +3 more
wiley   +1 more source

Successful bimekizumab retreatment after secondary failure in multi‐biologic‐resistant psoriasis

open access: yes
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nicole Kah Mun Yoong   +4 more
wiley   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

open access: yesInternational Journal of Dermatology, Volume 65, Issue 12, Page 2524-2531, December 2026.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel   +15 more
wiley   +1 more source

Medical reasons for patients who missed an etanercept dose.

open access: yes, 2018
Medical reasons for patients who missed an etanercept dose.
J. W. F. Kruijff (5832581)   +7 more
core   +1 more source

Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications

open access: yesImmunology, Volume 179, Issue 4, Page 565-578, December 2026.
PSTPIP2 acts as a key brake on myeloid inflammation by suppressing IL‐1β‐driven signalling, macrophage dysregulation and inflammation‐associated bone remodelling. Its emerging roles in CRMO/CMO, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid support its potential as a biomarker and therapeutic target.
Erdong Zhang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy